Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncopeptides ABCHIX:ONCOS 46 Equity-to-Asset is 0.28 as of Mar. 2026, which is 58% below its 10-year median of 0.67. GuruFocus rates CHIX:ONCOS with a GF Score™ of 46/100 and a GF Value™ of kr5.80 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,415 Biotechnology companies, Oncopeptides AB ranks worse than 79.65% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Oncopeptides AB's Total Stockholders Equity for the quarter that ended in Mar. 2026 was kr76.79 Mil. Oncopeptides AB's Total Assets for the quarter that ended in Mar. 2026 was kr271.89 Mil.
Therefore, Oncopeptides AB's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.28.
The historical rank and industry rank for Oncopeptides AB's Equity-to-Asset or its related term are showing as below:
CHIX:ONCOs'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.49 Med: 0.67 Max: 0.9
Current: 0.28
During the past 12 years, the highest Equity to Asset Ratio of Oncopeptides AB was 0.90. The lowest was -0.49. And the median was 0.67.
CHIX:ONCOs's Equity-to-Asset is ranked worse than 79.65% of 1415
companies
in the Biotechnology industry
Industry Median: 0.68
vs CHIX:ONCOs: 0.28
Oncopeptides AB (CHIX:ONCOs) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Oncopeptides AB Equity-to-Asset Related Terms
Oncopeptides AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Oncopeptides AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ONCOS vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Oncopeptides AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncopeptides AB Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncopeptides AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Oncopeptides AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Oncopeptides AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncopeptides AB (CHIX:ONCOS) has a Equity-to-Asset of 0.28 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Oncopeptides AB and its competitors. This is 58% below median its historical median of 0.67. According to the industry distribution chart, Oncopeptides AB ranks #1127 out of 1415 companies in the Biotechnology industry, placing it in the top 79.6%.
Is Oncopeptides AB's Equity-to-Asset too high?
Oncopeptides AB's current Equity-to-Asset of 0.28 is 58% below median its 10-year median of 0.67. The Biotechnology industry median Equity-to-Asset is 0.68. Oncopeptides AB's value of 0.28 is 58.8% below this industry median. Based on the distribution chart, Oncopeptides AB ranks #1127 out of 1415 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oncopeptides AB has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncopeptides AB ranks #1127 out of 1415 companies for Equity-to-Asset. This places Oncopeptides AB in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Oncopeptides AB's value of 0.28 is 58.8% below this benchmark. While the company's 10-year median is 0.67 vs. the industry median of 0.68, Oncopeptides AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncopeptides AB's current Equity-to-Asset of 0.28 is 58.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Oncopeptides AB and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncopeptides AB's current Equity-to-Asset is 0.28, which is 58% below median its own 10-year median of 0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (CHIX:ONCOS) is currently considered Possible Value Trap. The stock's GF Value™ is kr5.80, compared to a current price of kr1.72 — trading 70.3% below its estimated fair value. The current Equity-to-Asset is 0.28, which is 58% below median its 10-year median of 0.67 and 58.8% below the Biotechnology industry median of 0.68. Oncopeptides AB's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Oncopeptides AB (CHIX:ONCOS), the current Equity-to-Asset is 0.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncopeptides AB (CHIX:ONCOS) Overvalued in 2026?
Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued.
The current stock price of kr1.72 is trading 70.3% below its estimated GF Value™ of kr5.80.
GuruFocus considers Oncopeptides AB to be Possible Value Trap.
Key valuation signals for CHIX:ONCOS:
Equity-to-Asset: 0.28 (58% below median its 10-year median of 0.67)
GF Value™: kr5.80 vs. price of kr1.72 (70.3% below fair value)
Industry Position: 58.8% below the Biotechnology median (#1127 of 1415)
No single metric tells the full story. See the CHIX:ONCOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
46GF Score
Get the complete analysis for CHIX:ONCOS
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ONCOS has been successfully added to your 
